Technical Review: The Clinical Evolution of Shape-Sensing Robotic Bronchoscopy in Integrated Management of Pulmonary Nodules
The proliferation of lung cancer screening has shifted the clinical challenge toward the management of small (<10mm), deep-seated peripheral nodules in patients with high-risk comorbidities. The recent clinical outcomes demonstrated by the Department of Thoracic Surgery at PUMCH signify that robotic intervention based on shape-sensing technology has reached a stage of mature clinical application.
From a clinical architecture perspective, this technology transcends the limitations of traditional Electromagnetic Navigation Bronchoscopy (ENB), which is often susceptible to metallic interference and respiratory motion artifacts. The robotic arms maintain constant tension within ultra-distal subsegmental bronchi, providing a stable mechanical foundation for histological sampling. Within PUMCH’s quality control protocol, real-time fusion with Cone-Beam CT (CBCT) allows clinicians to verify the precise trajectory of ablation needles through the lesion center, achieving sub-millimeter spatial accuracy.
As a third-party facilitation agency, our evaluation of this clinical pathway focuses on three core dimensions:
-
Safety Metrics: Compared to the 15%-25% pneumothorax rate associated with percutaneous biopsy (TTNA), the robotic natural orifice transluminal approach reduces such complications to negligible levels—a decisive factor for elderly patients with limited pulmonary reserve.
-
Diagnostic Yield: The system’s high-sensitivity haptic feedback significantly enhances the biopsy positivity rate for both solid and ground-glass nodules (GGN).
-
Therapeutic Consistency: The immediate transition from "biopsy to ablation" eliminates the risks of repeated anesthesia and drastically shortens the clinical window from diagnosis to definitive treatment.
As a national center for rare and complex diseases, PUMCH’s exploration in this field represents more than a technological upgrade; it is a redefinition of clinical indication standards for early-stage lung cancer. We remain committed to facilitating access to top-tier clinical centers with these closed-loop capabilities, ensuring every medical intervention aligns with rigorous evidence-based logic.